What is Phylos Bioscience?
Phylos Bioscience operates at the intersection of molecular genetics and industrial agriculture, serving as a premier provider of cannabis genomics. The company utilizes advanced computational biology to drive the development and optimization of hemp and drug varieties, ensuring superior performance across diverse environmental conditions. By offering a comprehensive suite of genetic testing solutions, Phylos supports global breeding partnerships and cultivation enterprises, effectively standardizing quality and yield metrics for the modern cannabis industry. Their market position is bolstered by a deep technical moat, allowing them to provide actionable insights that traditional agricultural firms cannot replicate.
How much funding has Phylos Bioscience raised?
Phylos Bioscience has raised a total of $16M across 3 funding rounds:
Private Equity
$1.4M
Unspecified
$7.6M
Debt
$7M
Private Equity (2015): $1.4M, investors not publicly disclosed
Unspecified (2022): $7.6M led by Accomplice, Merida Capital Holdings, and Entourage Effect Capital
Debt (2024): $7M supported by OrganiGram
Key Investors in Phylos Bioscience
OrganiGram
Organigram is a leading producer of high-quality, indoor-grown cannabis, focused on developing international business partnerships and a diverse portfolio of legal adult-use recreational brands.
Accomplice
A venture capital firm specializing in early-stage technology investments, providing strategic guidance and capital to high-growth startups.
Merida Capital Holdings
A private equity firm focused on the cannabis ecosystem, providing capital to companies that demonstrate strong operational potential and market leadership.
What's next for Phylos Bioscience?
With the recent influx of capital, Phylos Bioscience is well-positioned to accelerate its research and development initiatives, focusing on the expansion of its genetic database and the refinement of its breeding technologies. The company is expected to prioritize the scaling of its international partnerships, leveraging its recent debt financing to optimize supply chain efficiencies and broaden its footprint in emerging global markets. As the industry moves toward greater standardization, Phylos is likely to focus on deepening its integration with large-scale cultivation operations, potentially exploring new diagnostic tools that enhance crop resilience and chemical consistency. This strategic focus on data-driven agricultural outcomes will be critical as the firm navigates the next phase of its enterprise-level growth.
See full Phylos Bioscience company page
